

HUMAN SURFACTANT PROTEIN D ELISA

Product Data Sheet

Cat No.: RD194059101

European Union:

IVD



Rest of the world: For research use only!

Page 1 of 28 VERSION 34 220311 44

CONTENTS

1.	INTENDED USE	3
2.	STORAGE, EXPIRATION	3
3.	INTRODUCTION	4
4.	TEST PRINCIPLE	4
5.	PRECAUTIONS	5
6.	TECHNICAL HINTS	5
7.	REAGENT SUPPLIED	6
8.	MATERIAL REQUIRED BUT NOT SUPPLIED	6
9.	PREPARATION OF REAGENTS	7
10.	PREPARATION OF SAMPLES	9
11.	ASSAY PROCEDURE	10
12.	CALCULATIONS	12
13.	PERFORMANCE CHARACTERISTICS	13
14.	DEFINITION OF THE STANDARD	17
15.	METHOD COMPARISON	18
16.	TROUBLESHOOTING AND FAQS	19
17.	REFERENCES	20
18.	EXPLANATION OF SYMBOLS	22

- This kit is manufactured by:
 BioVendor Laboratorní medicína a.s.
- **>>** Use only the current version of Product Data Sheet enclosed with the kit!

Page 2 of 28 VERSION 34 220311 44

1. INTENDED USE

The RD194059101 Human Surfactant Protein D ELISA is a sandwich enzyme immunoassay for the quantitative measurement of human surfactant protein D.

>> Features

- European Union: for in vitro diagnostic use Rest of the world: for research use only!
- The total assay time is less than 5 hours
- The kit measures total surfactant protein D in serum, plasma (EDTA, citrate, heparin), bronchoalveolar lavage fluid and amniotic fluid
- Assay format is 96 wells
- Quality Controls are human serum based. No animal sera are used
- Standards are recombinant protein based
- Components of the kit are provided ready to use, concentrated or lyophilized

2. STORAGE, EXPIRATION

Store the complete kit at 2-8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

For stability of opened reagents see Chapter 9.

Page 3 of 28 VERSION 34 220311 44

3. INTRODUCTION

Human Surfactant Protein D (SP-D) is a member of the collageneous subfamily of glycoproteins and calcium-dependent lectins (collectins).

SP-D is a homotrimeric protein consisting of three 43kDa units that are bonded at their N-termini. Most preparations of SP-D contain predominantly dodecamers (four trimeric subunits), but also higher multimers have been observed. Each unit consists of at least four discrete structural domains: a short N-terminal domain; a relatively long collagenous domain, a short amphipathic connecting peptide, and a C-terminal, C- type lectin carbohydrate recognition domain (CRD).

SP-D is synthesized and secreted by two types of non-ciliated epithelial cells in the peripheral airway, alveolar type II cells and Clara cells. It is also expressed by various epithelial cells in the gastrointestinal and genitourinary tracts. In the lungs, SP-D participates in the innate response to inhaled microorganisms and organic antigens. SP-D binds to surface glycoconjugates of various microorganisms and to oligosaccharides associated with the surface of numerous organic antigens.

Studies have shown that SP-D expression may be related to a number of human diseases: cystic fibrosis, acute interstitial pneumonias (ARDS), asthma, bronchopulmonary dysplasia, alveolar proteinosis, etc.

Animal studies have shown increased levels of SP-D expression in cases of silicosis and hyperoxia (in rat models) as well as IL-4 overexpression and invasion of infectious agents (in mouse models).

Areas of investigation:
Infection and inflammation
Lung disease

4. TEST PRINCIPLE

In the BioVendor Human Surfactant Protein D ELISA, Standards, Quality Controls and samples are incubated in microplate wells pre-coated with monoclonal anti-human surfactant protein D antibody. After 120 minutes incubation and washing, biotin labelled monoclonal anti-human SP-D antibody is added and incubated with the captured SP-D for 60 minutes. After another washing, streptavidin-HRP conjugate is added. After 60 minutes incubation and the last washing step, the remaining HRP conjugate is allowed to react with the substrate solution (TMB). The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured. The absorbance is proportional to the concentration of surfactant protein D. A standard curve is constructed by plotting absorbance values against concentrations of standards, and concentrations of unknown samples are determined using this standard curve.

Page 4 of 28 VERSION 34 220311 44

5. PRECAUTIONS

For professional use only

- Wear gloves and laboratory coats when handling immunodiagnostic materials
- Do not drink, eat or smoke in the areas where immunodiagnostic materials are being handled
- This kit contains components of human origin. These materials were found non-reactive for HBsAg, HCV antibody and for HIV 1/2 antigen and antibody. However, these materials should be handled as potentially infectious, as no test can guarantee the complete absence of infectious agents
- Avoid contact with the acidic Stop Solution and Substrate Solution, which contains hydrogen peroxide and tetramethylbenzidine (TMB). Wear gloves and eye and clothing protection when handling these reagents. Stop and/or Substrate Solutions may cause skin/eyes irritation. In case of contact with the Stop Solution and the Substrate Solution wash skin/eyes thoroughly with water and seek medical attention, when necessary
- The materials must not be pipetted by mouth

6. TECHNICAL HINTS

- Reagents with different lot numbers should not be mixed
- Use thoroughly clean glassware
- Use deionized (distilled) water, stored in clean containers
- Avoid any contamination among samples and reagents. For this purpose, disposable tips should be used for each sample and reagent
- Substrate Solution should remain colourless until added to the plate. Keep Substrate Solution protected from light
- Stop Solution should remain colourless until added to the plate. The colour developed in the wells will turn from blue to yellow immediately after the addition of the Stop Solution. Wells that are green in colour indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution
- Dispose of consumable materials and unused contents in accordance with applicable national regulatory requirements

Page 5 of 28 VERSION 34 220311 44

7. REAGENT SUPPLIED

Kit Components	State	Quantity
Antibody Coated Microtiter Strips	ready to use	96 wells
Biotin Labelled Antibody	ready to use	13 ml
Streptavidin-HRP Conjugate	ready to use	13 ml
Master Standards	lyophilized	1 vial
Quality Control HIGH	lyophilized	2 vials
Quality Control LOW	lyophilized	2 vials
Dilution Buffer	ready to use	50 ml
Wash Solution Conc. (10x)	concentrated	100 ml
Substrate Solution	ready to use	13 ml
Stop Solution	ready to use	13 ml
Product Data Sheet + Certificate of Analysis	-	1 pc

8. MATERIAL REQUIRED BUT NOT SUPPLIED

- Deionized (distilled) water
- Test tubes for diluting samples
- Glassware (graduated cylinder and bottle) for Wash Solution (Dilution Buffer)
- Precision pipettes to deliver 10-1000 µl with disposable tips
- \bullet Multichannel pipette to deliver 100 μl with disposable tips
- Absorbent material (e.g. paper towels) for blotting the microtitrate plate after washing
- Vortex mixer
- Orbital microplate shaker capable of approximately 300 rpm
- Microplate washer (optional). [Manual washing is possible but not preferable.]
- Microplate reader with 450 \pm 10 nm filter, preferably with reference wavelength 630 nm (alternatively another one from the interval 550-650nm)
- Software package facilitating data generation and analysis (optional)

Page 6 of 28 VERSION 34 220311 44

9. PREPARATION OF REAGENTS

- All reagents need to be brought to room temperature prior to use
- Always prepare only the appropriate quantity of reagents for your test
- Do not use components after the expiration date marked on their label
- Assay reagents supplied ready to use:

Antibody Coated Microtiter Strips

Stability and storage:

Return the unused strips to the provided aluminium zip-sealed bag with desicant and seal carefully. Remaining Microtiter Strips are stable 3 months stored at 2-8°C and protected from the moisture.

Biotin Labelled Antibody Streptavidin-HRP Conjugate Dilution Buffer Substrate Solution Stop Solution

Stability and storage:

Opened reagents are stable 3 months when stored at 2-8°C.

Assay reagents supplied concentrated or lyophilized:

Master Standard

Refer to the Certificate of Analysis for current volume of Dilution Buffer needed for reconstitution of standard!!!

Reconstitute the lyophilized Master Standard with Dilution Buffer just prior to the assay. Let it dissolve at least 15 minutes with occasional gentle shaking (not to foam). The resulting concentration of the SP-D in the stock solution is **100 ng/ml**.

Page 7 of 28 VERSION 34 220311 44

Prepare set of standards using Dilution Buffer as follows:

Volume of Standard	Dilution Buffer	Concentration
Stock	-	100 ng/ml
300 μl of stock	300 μl	50 ng/ml
300 μl of 50 ng/ml	300 μl	25 ng/ml
300 μl of 25 ng/ml	300 μl	12.5 ng/ml
300 μl of 12.5 ng/ml	300 μl	6.25 ng/ml
300 μl of 6.25 ng/ml	300 μΙ	3.13 ng/ml
300 μl of 3.13 ng/ml	300 μl	1.56 ng/ml

Prepared Standards are ready to use, do not dilute them.

Stability and storage:

Reconstituted Master Standard (100 ng/ml) must be used immediately or aliquoted and frozen at –20°C for 3 months. Avoid repeated freeze/thaw cycles.

Do not store the diluted Standard solutions.

Quality Controls HIGH, LOW

Refer to the Certificate of Analysis for current volume of Dilution Buffer needed for reconstitution and for current Quality Control concentration!!!

Reconstitute each Quality Control (HIGH and LOW) with Dilution Buffer just prior to the assay. Let it dissolve at least 15 minutes with occasional gentle shaking (not to foam).

Stability and storage:

Do not store the reconstituted Quality Controls.

Wash Solution Conc. (10x)

Dilute Wash Solution Concentrate (10x) 10-fold in distilled water to prepare a 1x working solution. Example: 100 ml of Wash Solution Concentrate (10x)+ 900 ml of distilled water for use of all 96-wells.

Stability and storage:

The diluted Wash Solution is stable 1 month when stored at 2-8°C. Opened Wash Solution Concentrate (10x) is stable 3 months when stored at 2-8°C.

Page 8 of 28 VERSION 34 220311 44

10. PREPARATION OF SAMPLES

The kit measures Surfactant Protein D in serum and plasma (EDTA, citrate, heparin), bronchoalveolar lavage fluid and amniotic fluid.

Samples should be assayed immediately after collection or should be stored at -20°C. Mix thoroughly thawed samples just prior to the assay and avoid repeated freeze/thaw cycles, which may cause erroneous results. Avoid using hemolyzed or lipemic samples.

Dilute samples 11x with Dilution Buffer just prior to the assay, e.g. 25 μ l of sample + 250 μ l of Dilution Buffer and **mix well** (not to foam). Vortex is recommended.

In case of measurement of SP-D in bronchoalveolar lavage fluid (BAL) an appropriate dilution should be assessed by the researcher in advance to batch measurement (recommended starting dilution is 40x, e.g. $10 \mu l$ of BAL sample + $390 \mu l$ of Dilution Buffer).

Stability and storage:

Samples should be stored at -20°, or preferably at -70°C for long-term storage. Avoid repeated freeze/ thaw cycles.

Do not store the diluted samples.

See Chapter 13 for stability of serum and plasma samples when stored at 2-8°C, effect of freezing/thawing and effect of sample matrix (serum/plasma) on the concentration of Surfactant Protein D.

Note: It is recommended to use a precision pipette and a careful technique to perform the dilution in order to get precise results.

Ask for protocol at <u>info@biovendor.com</u> if assaying bronchoalveolar lavage fluid, amniotic fluid and tissue culture medium.

Page 9 of 28 VERSION 34 220311 44

11. ASSAY PROCEDURE

- 1. Pipet **100** μI of Standards, Quality Controls, Dilution Buffer (=Blank) and samples, preferably in duplicates, into the appropriate wells. See *Figure 1* for example of work sheet.
- 2. Incubate the plate at 25°C for **2 hours**, shaking at ca. 300 rpm on an orbital microplate shaker.
 - <u>Incubation temperature is a critical factor for the assay. Performing the incubation at the temperature of 25°C is crucial in order to obtain valuable results!!!</u>
- 3. Wash the wells 5-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.
- 4. Add **100** μ**I** of Biotin Labelled Antibody solution into each well.
- 5. Incubate the plate at 25°C for **1 hour**, shaking at ca. 300 rpm on an orbital microplate shaker.
 - Incubation temperature is a critical factor for the assay. Performing the incubation at the temperature of 25°C is crucial in order to obtain valuable results!!!
- 6. Wash the wells 5-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.
- 7. Add **100** μ**I** of Streptavidin-HRP Conjugate into each well.
- 8. Incubate the plate at 25°C for **1 hour**, shaking at ca. 300 rpm on an orbital microplate shaker.
 - Incubation temperature is a critical factor for the assay. Performing the incubation at the temperature of 25°C is crucial in order to obtain valuable results!!!
- 9. Wash the wells 5-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.
- 10. Add 100 μ I of Substrate Solution into each well. Avoid exposing the microtiter plate to direct sunlight. Covering the plate with e.g. aluminium foil is recommended.
- 11. Incubate the plate for **15 minutes** at room temperature. The incubation time may be extended [up to 20 minutes] if the reaction temperature is below than 20°C. Do not shake the plate during the incubation.
- 12. Stop the colour development by adding 100 μ I of Stop Solution.
- 13. Determine the absorbance of each well using a microplate reader set to 450 nm, preferably with the reference wavelength set to 630 nm (acceptable range: 550 650 nm). Subtract readings at 630 nm (550 650 nm) from the readings at 450 nm. The absorbance should be read within 5 minutes following step 12.

Note: If some samples and standard/s have absorbances above the upper limit of your microplate reader, perform a second reading at 405 nm. A new standard curve, constructed using the values measured at 405 nm, is used to determine SP-D concentration of off-scale standards and samples. The readings at 405 nm should not replace the readings for samples that were "in range" at 450 nm.

Page 10 of 28 VERSION 34 220311 44

Note 2: Manual washing: Aspirate wells and pipet 0.35 ml Wash Solution into each well. Aspirate wells and repeat four times. After final wash, invert and tap the plate strongly against paper towel. Make certain that Wash Solution has been removed entirely.

	strip 1+2	strip 3+4	strip 5+6	strip 7+8	strip 9+10	strip 11+12
Α	Standard 100	QC HIGH	Sample 7	Sample 15	Sample 23	Sample 31
В	Standard 50	QC LOW	Sample 8	Sample 16	Sample 24	Sample 32
С	Standard 25	Sample 1	Sample 9	Sample 17	Sample 25	Sample 33
D	Standard 12.5	Sample 2	Sample 10	Sample 18	Sample 26	Sample 34
Е	Standard 6.25	Sample 3	Sample 11	Sample 19	Sample 27	Sample 35
F	Standard 3.13	Sample 4	Sample 12	Sample 20	Sample 28	Sample 36
G	Standard 1.56	Sample 5	Sample 13	Sample 21	Sample 29	Sample 37
Н	Blank	Sample 6	Sample 14	Sample 22	Sample 30	Sample 38

Figure 1: Example of a work sheet.

Page 11 of 28 VERSION 34 220311 44

12. CALCULATIONS

Most microplate readers perform automatic calculations of analyte concentration. The standard curve is constructed by plotting the mean absorbance (Y) of Standards against the known concentration (X) of Standards in logarithmic scale, using the four-parameter algorithm. Results are reported as concentration of Surfactant Protein D (ng/ml) in samples.

Alternatively, the logit log function can be used to linearize the standard curve, i.e. logit of the mean absorbance (Y) is plotted against log of the known concentration (X) of Standards.

The measured concentration of samples calculated from the standard curve must be multiplied by their respective dilution factor, because samples have been diluted prior to the assay, e.g. 13.5 ng/ml (from standard curve) x 11 (dilution factor) = 148.5 ng/ml.




Figure 2: Typical Standard Curve for Human SP-D ELISA.

Page 12 of 28 VERSION 34 220311 44

13. PERFORMANCE CHARACTERISTICS

Typical analytical data of BioVendor Human Surfactant Protein D ELISA are presented in this chapter

Sensitivity

Limit of Detection (LOD) (defined as concentration of analyte giving absorbance higher than mean absorbance of blank* plus three standard deviations of the absorbance of blank: A_{blank} + 3xSD_{blank}) is calculated from the real SP-D values in wells and is 0.01 ng/ml. *Dilution Buffer is pipetted into blank wells.

Limit of assay

Results exceeding SP-D level of 100 ng/ml should be repeated with more diluted samples. Dilution factor needs to be taken into consideration in calculating the SP-D concentration.

Specificity

The monoclonal antibodies used in this ELISA are specific for human surfactant protein D.

Sera of several mammalian species were measured in the assay. See results below. For details please contact us at info@biovendor.com.

Mammalian serum sample	Observed crossreactivity
Bovine	yes
Cat	no
Dog	no
Goat	no
Hamster	no
Horse	yes
Monkey	yes
Mouse	no
Pig	no
Rabbit	no
Rat	no
Sheep	no

Page 13 of 28 VERSION 34 220311 44

Presented results are multiplied by respective dilution factor

Precision

Intra-assay (Within-Run) (n=8)

Sample	Mean	SD	CV
	(ng/ml)	(ng/ml)	(%)
1	78.76	1.67	2.1
2	135.07	3.12	2.3

Inter assay (Run-to-Run) (n=5)

mitor accay	(i tail to i tail) (ii o	/	
Sample	Mean	SD	CV
	(ng/ml)	(ng/ml)	(%)
1	79.30	1.91	2.4
2	138.13	5.13	3.7

Spiking Recovery

Serum samples were spiked with different amounts of human SP-D and assayed.

Sample	O bserved	E xpected	Recovery O/E
	(ng/ml)	(ng/ml)	(%)
1	55.55	-	-
	65.13	68.05	95.7
	79.51	80.55	98.7
	101.81	105.55	96.5
2	76.79	-	-
	82.32	89.29	92.2
	96.76	101.79	95.1
	120.68	126.79	95.2

Linearity

Serum samples were serially diluted with Dilution Buffer and assayed.

Sample	Dilution	O bserved	E xpected	Recovery
		(ng/ml)	(ng/ml)	O/E (%)
1	-	134.40	-	-
	2x	63.09	67.20	93.9
	4x	32.79	33.60	97.6
	8x	14.53	16.80	86.5
2	-	199.12	-	-
	2x	100.58	99.56	101.0
	4x	52.02	49.78	104.5
	8x	24.64	24.89	99.0

Page 14 of 28 VERSION 34 220311 44

Effect of sample matrix

Heparin, citrate and EDTA plasmas were compared to respective serum samples from the same 10 individuals.

Results are shown below:

Volunteer	Serum	Pi	asma (ng/	/ml)
No.	(ng/ml)	EDTA	Citrate	Heparin
1	82.13	65.01	66.74	71.20
2	87.39	82.17	73.00	86.60
3	59.60	51.54	56.01	52.02
4	45.90	40.30	38.04	40.74
5	94.56	88.17	80.49	85.20
6	117.16	117.52	105.53	115.20
7	86.35	71.42	65.43	75.71
8	45.06	32.35	34.10	39.40
9	119.02	113.85	105.82	102.23
10	60.06	51.64	46.94	51.06
Mean (ng/ml)	79.72	71.94	67.21	71.94
Mean Plasma/Serum		89.6	84.3	90.2
(%)				
Coefficient of		0.97	0.97	0.97
determination R ²				




Figure 3: SP-D levels measured using Human SP-D ELISA from 10 individuals using serum, heparin, citrate and EDTA plasma, respectively.

Page 15 of 28 VERSION 34 220311 44

Stability of samples stored at 2-8°C

Samples should be stored at -20°C, or preferably at -70°C. However, no decline in concentration of SP-D was observed in serum and plasma samples after 7 days when stored at 2-8°C. To avoid microbial contamination, samples were treated with ε -aminocaproic acid and sodium azide, resulting in the final concentration of 0.03% and 0.1%, respectively.

Sample	Incubation	Serum	m Plasma (ng/ml)		
	Temp, Period	(ng/ml)	EDTA	Citrate	Heparin
	-20°C	105.18	92.41	86.32	93.13
1	2-8°C, 1 day	89.66	85.38	83.61	93.31
	2-8°C, 7 days	90.72	76.62	78.70	88.71
	-20°C	205.30	165.84	175.85	161.44
2	2-8°C, 1 day	206.10	162.90	171.28	162.61
	2-8°C, 7 days	187.85	157.67	167.62	146.49
	-20°C	64.72	52.51	55.14	61.84
3	2-8°C, 1 day	65.36	51.75	50.46	58.69
	2-8°C, 7 days	58.98	47.71	52.61	58.86

• Effect of Freezing/Thawing

No decline was observed in concentration of human SP-D in serum and plasma samples after repeated (5x) freeze/thaw cycles. However it is recommended to avoid unnecessary repeated freezing/thawing of the samples.

Sample	Number of f/t	Serum	Plasma (ng/ml)		
Sample	cycles	(ng/ml)	EDTA	Citrate	Heparin
	1x	91.29	92.79	83.35	70.95
1	3x	95.32	91.29	83.95	74.84
	5x	94.26	97.79	83.63	73.78
	1x	57.24	50.27	48.13	52.63
2	3x	52.50	50.14	49.59	52.50
	5x	54.54	48.67	51.70	52.89
	1x	44.02	31.27	31.98	48.48
3	3x	40.40	23.79	24.02	40.09
	5x	38.43	22.90	30.11	40.62

Page 16 of 28 VERSION 34 220311 44

Distribution of SP-D in BAL and amniotic fluid samples

BAL samples were taken from 14 patients, amniotic fluid samples were taken from 10 woman and measured in the assay. Results are shown below:

	Mean	Minimum value	Maximum value		
Samples	(ng/ml)	(ng/ml)	(ng/ml)		
BALF	363.24	14.98	2690.67		
Amniotic fluid (first trimester)	21.05	9.63	38.71		
Amniotic fluid (third trimester)	5561.55	3364.69	7875.27		

Reference range

It is recommended that each laboratory include its own panel of control sample in the assay. Each laboratory should establish its own normal and pathological reference ranges for SP-D levels with the assay.

14. DEFINITION OF THE STANDARD

A recombinant protein is used as the standard. The recombinant human SP-D is oligomer consisting of 355 amino acid polypeptide chains.

Page 17 of 28 VERSION 34 220311 44

15. METHOD COMPARISON

The BioVendor Surfactant Protein D ELISA was compared to the previous version of the ELISA (Cat. No. RD194059100). The following correlation graph was obtained.




Figure 4: Method comparison.

Page 18 of 28 VERSION 34 220311 44

16. TROUBLESHOOTING AND FAQS

Weak signal in all wells

Possible explanations:

- Omission of a reagent or a step
- Improper preparation or storage of a reagent
- Assay performed before reagents were allowed to come to room temperature
- Improper wavelength when reading absorbance

High signal and background in all wells

Possible explanations:

- Improper or inadequate washing
- Overdeveloping; incubation time with Substrate Solution should be decreased before addition of Stop Solution
- Incubation temperature over 30°C

>> High coefficient of variation (CV)

Possible explanation:

- Improper or inadequate washing
- Improper mixing Standards, Quality Controls or samples

>> High signal of controls and samples

Possible explanations:

• First incubation temperature over 30°C. Performing the incubation at the temperature of 25°C is crucial in order to obtain valuable results!!!

Page 19 of 28 VERSION 34 220311 44

17. REFERENCES

>> References to SP-D:

- Tanaka S., Satoh T., Nagae H., Hamaoki M., Nagata A.. Igaku To Yakugaku (Japanese) 59, 439-446 (2008)
- Crouch E.C: Surfactant protein-D and pulmonary host defense. Respir Res, **1**(2):93-108, (2000)
- Honda Y., Kuroki Y., Matsuura E., et al.: Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am. J. Respir. Crit. Care Med., **152**: 1860-1886, (1995)
- Inoue T., Matsuura E., Nagata A. et al.: Enzyme- linked immunosorbent assay for human pulmonary surfactant protein D. J. Immunol. Methods, **173**: 157-164, (1994)
- Takahashi H., Kuroki Y., Abe S at al.: Serum Surfactant Proteins A and D as Prognostic Factors in Idiopathic Pulmonary Fibrosis and Their Relationship to Disease Extent. Am. J. Respir. Crit. Care Med., **162**: 1109-1114, (2000)
- Ohnishi H., Hiwada K., Kohno N. et al.: Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein D, and Monocyte Chemoattractant Protein –1 as Serum Markers for Interstitial Lung Diseases. Am. J. Respir. Crit. Care Med., 165: 378-381, (2002)
- Nagae H., Takahashi H., Kuroki Y. et al.: Enzyme-linked immunosorbent assay using F(ab')2 fragment for the detection of human pulmonary surfactant protein D in sera. Clim. Chim. Acta, 266: 157-161, (1997)
- Greene K., Martin T. et al.: Serial Changes in Surfactant-associated Proteins in Lung and Serum before and after Onset of ARDS. Am. J. Respir. Crit. Care Med., **160**: 1843-1850, (1999)
- Takahashi H., Kuroki Y., Tanaka H., Saito T., Kurokawa K., Chiba H., Sagawa A., Nagae H., Abe S.: Serum Levels of Surfactant Proteins A and D Are Useful Biomarkers for Interstitial Lung Disease in Patients with Progressive Systemic Sclerosis. Am. J. Respir. Crit. Care Med., 162: 258-263, (2000)
- Takahashi H., Kuroki Y., Abe S at al.: Serum Surfactant Proteins A and D as Prognostic Factors in Idiopathic Pulmonary Fibrosis and Their Relationship to Disease Extent. Am. J. Respir. Crit. Care Med., **162**: 1109-1114, (2000)
- Schnapp L.M., Donohoe S., Chen J., Sunde D.A., Kelly P.M., Ruzinski J., Martin T., Goodlett D.R.: Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. Am J Pathol . Jul;169(1):86-95 (2006)
- Erpenbeck V.J., Ziegert M., Cavalet-Blanco D., Martin C., Baelder R., Glaab T., Braun A., Steinhilber W., Luettig B., Uhlig S., Hoymann H.G., Krug N., Hohlfeld J.M.: Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice. Clin Exp Allergy . 36(7):930-40 (2006)
- Nickmilder M., Carbonnelle S., Bernard A.: House cleaning with chlorine bleach and the risks of allergic and respiratory diseases in children. *Pediatr Allergy Immunol*. Feb;18(1):27-35 (2007)

Page 20 of 28 VERSION 34 220311 44

- Sorensen G.L., Husby S., Holmskov U.: Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology . 212(4-5):381-416 (2007)
- Sims M.W., Tal-Singer R.M., Kierstein S., Musani Al., Beers M.F., Panettieri R.A., Haczku A..: Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res. 2008;9:13

For more references on this product see our WebPages at www.biovendor.com


Page 21 of 28 VERSION 34 220311 44

18. EXPLANATION OF SYMBOLS

REF	Catalogue number		
Cont.	Content		
LOT	Lot number		
<u> </u>	See instructions for use		
	Biological hazard		
	Expiry date		
2 °C 8 °C	Storage conditions		
25 PP	Identification of packaging materials		
IVD (€	In vitro diagnostic medical device		

Page 22 of 28 VERSION 34 220311 44

Assay Procedure Summary



Page 23 of 28 VERSION 34 220311 44

က				
4				
S.				
2 9				
∞				
တ				
10				
7				
12				

NOTES


Page 24 of 28 VERSION 34 220311 44

Page 25 of 28 VERSION 34 220311 44

Page 26 of 28 VERSION 34 220311 44

Page 27 of 28 VERSION 34 220311 44





HEADQUARTERS: BioVendor - Laboratorní medicína a.s.	Karasek 1767/1	621 00 Brno CZECH REPUBLIC	Phone: Fax:	+420-549-124-185 +420-549-211-460	E-mail: Web:	info@biovendor.com www.biovendor.com
EUROPEAN UNION: BioVendor GmbH	Im Neuenheimer Feld 583	D-69120 Heidelberg GERMANY	Phone: Fax:	+49-6221-433-9100 +49-6221-433-9111	E-mail:	infoEU@biovendor.com
USA, CANADA AND MEXICO: BioVendor LLC	1463 Sand Hill Road Suite 227	Candler, NC 28715 USA	Phone: Fax:	+1-828-670-7807 +1-800-404-7807 +1-828-670-7809	E-mail:	infoUSA@biovendor.com
CHINA - Hong Kong Office: BioVendor Laboratories Ltd	Room 4008 Hong Kong Plaza, No.188	Connaught Road West Hong Kong, CHINA	Phone: Fax:	+852-2803-0523 +852-2803-0525	E-mail:	infoHK@biovendor.com
CHINA – Mainland Office: BioVendor Laboratories Ltd	Room 2917, 29/F R & F Ying Feng Plaza, No.2 Huagiang road	Pearl River New Town Guang Zhou, CHINA	Phone: Fax:	+86-20-38065519 +86-20-38065529	E-mail:	infoCN@biovendor.com

Page 28 of 28 VERSION 34 220311 44